LBPS - Earnings announcements

- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet

- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.